Press Releases | Y-mAbs Therapeutics, Inc.

Year

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

NEW YORK , May 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

May 26, 2022

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

Completed resubmission to the FDA of omburtamab BLA DANYELZA® adoption drove a 9% sequential revenue increase to $10.5 million Company issues 2022 full-year DANYELZA® revenue guidance of $45-$50 million Strong cash position with $156.7 million as of March 31, 2022 , providing runway through

May 09, 2022

Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

NEW YORK , May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31, 2022 on Monday, May 9, 2022 , after the close of the U.S. financial markets.

May 03, 2022

Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update

CEO and Board Member Dr. Claus Moller has stepped down; Thomas Gad , Founder, Chairman and President assumes Interim CEO role and steps down as Chairman; Dr. Jim Healy to be appointed as Chairman DANYELZA® first quarter revenues were $10.5 million , up 9% sequentially quarter over quarter

Apr 27, 2022

Y-mAbs Announces Presentation of SADA Technology at AACR

NEW YORK , April 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Apr 08, 2022

Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

NEW YORK , April 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Apr 01, 2022

Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

Announced completion of pre-BLA meeting with the FDA for omburtamab BLA resubmission expected by the end of first quarter 2022 DANYELZA® adoption drives sequential revenue increase Completed IND submission to the FDA for first SADA construct Appointed Sue Smith as Chief Commercial Officer Strong

Feb 24, 2022

Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022

NEW YORK , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December 31, 2021 on Thursday, February 24, 2022 , after the close of the U.S. financial markets.

Feb 17, 2022

Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab

NEW YORK , Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Feb 11, 2022

Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

NEW YORK , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Jan 05, 2022